Table of Contents
ISRN Obstetrics and Gynecology
Volume 2011, Article ID 724649, 4 pages
http://dx.doi.org/10.5402/2011/724649
Review Article

Controversies in the Adjuvant Therapy of Endometrial Cancer

1Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei 220, Taiwan
2Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100, Taiwan
3Department of Oncology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100, Taiwan

Received 26 June 2011; Accepted 2 August 2011

Academic Editors: M. A. Lumsden, A. Martin-Hidalgo, and Y. S. Song

Copyright © 2011 Sheng-Mou Hsiao and Lin-Hung Wei. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Kuoppala, J. Mäenpää, E. Tomas et al., “Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy,” Gynecologic Oncology, vol. 110, no. 2, pp. 190–195, 2008. View at Publisher · View at Google Scholar · View at PubMed
  2. S. Pecorelli, “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium,” International Journal of Gynecology and Obstetrics, vol. 105, no. 2, pp. 103–104, 2009. View at Google Scholar
  3. “NCCN Clinical practice guidelines in oncology (NCCN GuidelinesTM) Uterine neoplasms version 1,” 2011, NCCN.org, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  4. B. Röper, S. T. Astner, A. Heydemann-Obradovic et al., “Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients,” Gynecologic Oncology, vol. 107, no. 3, pp. 541–548, 2007. View at Publisher · View at Google Scholar · View at PubMed
  5. C. P. Morrow, B. N. Bundy, R. Kurman et al., “Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium (a gynecologic oncology group study),” Gynecologic Oncology, vol. 40, no. 1, pp. 55–65, 1991. View at Publisher · View at Google Scholar
  6. H. M. Keys, J. A. Roberts, V. L. Brunetto et al., “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study,” Gynecologic Oncology, vol. 92, no. 3, pp. 744–751, 2004. View at Publisher · View at Google Scholar · View at PubMed
  7. J. M. Straughn Jr., W. K. Huh, F. J. Kelly et al., “Conservative management of Stage I endometrial carcinoma after surgical staging,” Gynecologic Oncology, vol. 84, no. 2, pp. 194–200, 2002. View at Publisher · View at Google Scholar · View at PubMed
  8. T. Hogberg, M. Fredstorp-Lidebring, P. Alm et al., “A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer,” International Journal of Gynecological Cancer, vol. 14, no. 3, pp. 437–450, 2004. View at Publisher · View at Google Scholar · View at PubMed
  9. C. L. Creutzberg, W. L. van Putten, P. C. Koper et al., “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC study group. Post operative radiation therapy in endometrial carcinoma,” The Lancet, vol. 355, no. 9213, pp. 1404–1411, 2000. View at Google Scholar
  10. A. N. Scholten, W. L. van Putten, H. Beerman et al., “Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 3, pp. 834–838, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. ASTEC/EN.5 Study Group, P. Blake, and A. M. Swart, “Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis,” The Lancet, vol. 373, no. 9658, pp. 137–146, 2009. View at Publisher · View at Google Scholar
  12. R. A. Nout, V. T. Smit, H. Putter et al., “Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial,” The Lancet, vol. 375, no. 9717, pp. 816–823, 2010. View at Publisher · View at Google Scholar
  13. R. A. Nout, H. Putter, I. M. Jürgenliemk-Schulz et al., “Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial,” Journal of Clinical Oncology, vol. 27, no. 21, pp. 3547–3556, 2009. View at Publisher · View at Google Scholar · View at PubMed
  14. A. Kong, N. Johnson, P. Cornes et al., “Adjuvant radiotherapy for stage I endometrial cancer,” Cochrane Database of Systematic Reviews, no. 2, CD003916, 2007. View at Publisher · View at Google Scholar · View at PubMed
  15. N. Susumu, S. Sagae, Y. Udagawa et al., “Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese gynecologic oncology group study,” Gynecologic Oncology, vol. 108, no. 1, pp. 226–233, 2008. View at Publisher · View at Google Scholar · View at PubMed
  16. D. S. McMeekin, “Pelvic radiation therapy or vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer,” 2011, ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT00807768. View at Google Scholar
  17. R. Maggi, A. Lissoni, F. Spina et al., “Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial,” British Journal of Cancer, vol. 95, no. 3, pp. 266–271, 2006. View at Publisher · View at Google Scholar · View at PubMed
  18. M. E. Randall, V. L. Filiaci, H. Muss et al., “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 36–44, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. M. S. Aapro, F. H. van Wijk, G. Bolis et al., “Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC gynaecological cancer group,” Annals of Oncology, vol. 14, no. 3, pp. 441–448, 2003. View at Publisher · View at Google Scholar
  20. M. A. Sovak, M. L. Hensley, J. Dupont et al., “Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study,” Gynecologic Oncology, vol. 103, no. 2, pp. 451–457, 2006. View at Publisher · View at Google Scholar · View at PubMed
  21. G. F. Fleming, V. L. Brunetto, D. Cella et al., “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2159–2166, 2004. View at Publisher · View at Google Scholar · View at PubMed
  22. D. S. Miller, “Combination chemotherapy in treating patients with stage III, stage IV, or recurrent endometrial cancer,” 2009, ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT00063999. View at Google Scholar
  23. A. H. Klopp, A. Jhingran, L. Ramondetta, K. Lu, D. M. Gershenson, and P. J. Eifel, “Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation,” Gynecologic Oncology, vol. 115, no. 1, pp. 6–11, 2009. View at Publisher · View at Google Scholar · View at PubMed
  24. T. Hogberg, P. Rosenberg, G. Kristensen et al., “A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991),” Journal of Clinical Oncology, vol. 25, supplement 18, p. 5503, 2007. View at Google Scholar
  25. C. L. Creutzberg, “Randomised phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial carcinoma: PORTEC-3,” 2006, Nederlands trial register, http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=729. View at Google Scholar
  26. D. E. Matei, “Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer,” 2001, ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT00942357. View at Google Scholar